A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine

Journal of Molecular Diagnostics

Volumn 13, Issue 5, 2011, Pages 474-484

  Lin, Selena Y ^a   Dhillon, Veerpal ^a   Jain, Surbhi ^a   Chang, Ting Tsung ^b   Hu, Chi Tan ^c   Lin, Yih Jyh ^d   Chen, Shun Hua ^b   Chang, Kung Chao ^b   Song, Wei ^e   Yu, Lixin ^a   Block, Timothy M ^a   Su, Ying Hsiu ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e JBS Science Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOCKED NUCLEIC ACID; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA ISOLATION; DNA SEQUENCE; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; URINALYSIS; WILD TYPE;

EID: 82755191709     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2011.05.005     Document Type: Article

References (51)

1. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687 (Pubitemid 44286000)
2. Kuang SY, Lekawanvijit S, Maneekarn N, Thongsawat S, Brodovicz K, Nelson K, Groopman JD: Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 2005, 14:380-384 (Pubitemid 40270100)
3. Jackson PE, Kuang SY, Wang JB, Strickland PT, Munoz A, Kensler TW, Qian GS, Groopman JD: Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 2003, 24:1657-1663 (Pubitemid 37304671)
4. Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K: The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology 1995, 22:1702-1707
5. Honda K, Sbisà E, Tullo A: p53 Mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 1998, 77:776-782 (Pubitemid 28077466)
6. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC: TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-2176 (Pubitemid 46536641)
7. Bressac B, Kew M, Wands J, Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431 (Pubitemid 21912246)
8. Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P, Trépo C, Bréchot C, Hainaut P, Montesano R: Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst 2000, 92:148-153 (Pubitemid 30089872)
9. Lleonart ME, Kirk GD, Villar S, Lesi OA, Dasgupta A, Goedert JJ, Mendy M, Hollstein MC, Montesano R, Groopman JD, Hainaut P, Friesen MD: Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomarkers Prev 2005, 14:2956-2962 (Pubitemid 43068831)
10. Jackson PE: Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res 2001, 61:33-35
11. Hosny G, Farahat N, Tayel H, Hainaut P: Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. Cancer Lett 2008, 264:201-208
12. Lichtenstein AV, Melkonyan HS, Tomei D, Umansky SR: Circulating nucleic acids and apoptosis. Ann N Y Acad Sci 2001, 945:239-249 (Pubitemid 33022460)
13. Su YH, Wang M, Brenner DE, Ng A, Melkonyan H, Umansky S, Syngal S, Block TM: Human urine contains small, 150 to 250 nucleotidesized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn 2004, 6:101-107
14. Chan AKC, Chiu RWK, Lo YMD: Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem 2003, 40:122-130 (Pubitemid 36359862)
15. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R: Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006, 52:1833-1842 (Pubitemid 44470688)
16. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr: Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990
17. Anker P, Lyautey J, Lederrey C, Stroun M: Circulating nucleic acids in plasma or serum. Clin Chim Acta 2001, 313:143-146 (Pubitemid 33016704)
18. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch R, Knippers R: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665 (Pubitemid 34292602)
19. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, Rossier A, Chen XQ, Anker P: The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2000, 906:161-168 (Pubitemid 30255476)
20. Su Y-H, Wang M, Norton PA, Brenner DE, Block TM: Detection of mutated K-ras DNA in urine, plasma and serum from patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci 2008, 1137:197-201
21. Chan KCA, Leung SF, Yeung SW, Chan ATC, Lo YMD: Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. Clin Cancer Res 2008, 14:4809-4813
22. Sikora A, Zimmermann G, Rusterholz C, Birri D, Kolla V, Lapaire O, Hoesli I, Kiefer V, Jackson L, Hahn S: Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin Chem 2010, 56:136-138
23. Shekhtman EM, Anne K, Melkonyan HS, Robbins DJ, Warsof SL, Umansky SR: Optimization of transrenal DNA analysis: detection of fetal DNA in maternal urine. Clin Chem 2009, 55:723-729
24. Nogueira ML, Wang VEH, Tantin D, Sharp PA, Kristie TM: Herpes simplex virus infections are arrested in Oct-1-deficient cells. Proc Natl Acad Sci U S A 2004, 101:1473-1478 (Pubitemid 38234179)
25. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P: Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994, 264:1317-1319 (Pubitemid 24219080)
26. Kirk GD, Lesi OA, Mendy M, Szymanska K, Whittle H, Goedert JJ, Hainaut P, Montesano R: 249Ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 2005, 24:5858-5867 (Pubitemid 43080077)
27. Igetei R, Otegbayo J, Ndububa D, Lesi O, Anumudu C, Hainaut P, Gormally E: Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. Ann Hepatol 2008, 7:339-344
28. Laken SJ, Jackson PE, Kinzler KW, Vogelstein B, Strickland PT, Groopman JD, Friesen MD: Genotyping by mass spectrometric analysis of short DNA fragments. Nature Biotechnol 1998, 16:1352-1356 (Pubitemid 28547447)
29. Katiyar S, Dash BC, Thakur V, Guptan RC, Sarin SK, Das BC: P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 2000, 88:1565-1573 (Pubitemid 30183141)
30. Su Y-H, Wang M, Aiamkitsumrit B, Brenner DE, Block TM: Detection of K-ras mutation in urine of patients with colorectal cancer. Cancer Biomark 2005, 1:177-182
31. Garcia C, Ahmadian A, Gharizadeh B, Lundeberg J, Ronaghi M, Nyrén P: Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene. Gene 2000, 253:249-257 (Pubitemid 30625216)
32. Arjomand-Nahad F, Diefenbach K, Landt O, Gaikovitch E, Roots I: Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. Anal Biochem 2004, 334:201-203 (Pubitemid 39304093)
33. Oldenburg RP, Liu MS, Kolodney MS: Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA. J Invest Dermatol 2009, 128:398-402
34. Ren XD, Lin SY, Wang X, Zhou T, Block TM, Su YH: Rapid and sensitive detection of hepatitis B virus 1762T/1764A double mutation from hepatocellular carcinomas using LNA-mediated PCR clamping and hybridization probes. J Virol Methods 2009, 158:24-29
35. Chase CJ, Ulrich MP, Wasieloski LP Jr, Kondig JP, Garrison J, Lindler LE, Kulesh DA: Real-time PCR assays targeting a unique chromosomal sequence of Yersinia pestis. Clin Chem 2005, 51:1778-1785 (Pubitemid 41368167)
36. Loveless BM, Yermakova A, Christensen DR, Kondig JP, Heine HS 3rd, Wasieloski LP, Kulesh DA: Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis. Mol Cell Probes 2010, 24:154-160
37. Valles-Ayoub Y, Saechao C, Haghighatgoo A, Neshat MS, Esfandiarifard S, Pietruszka M, Darvish D: Validation of GNE: p.M712T identification by melting curve analysis. Genet Test 2008, 12:101-109 (Pubitemid 351457779)
38. Klaassen CHW, van Aarssen YAWG, van der Stappen JWJ: Improved real-time detection of the H63D and S65C mutations associated with hereditary hemochromatosis using a SimpleProbe assay format. Clin Chem Lab Med 2008, 46:985-986 (Pubitemid 352000501)
39. Monteros MJ, Ha B, Phillips DV, Boerma HR: SNP assay to detect the "Hyuuga" red-brown lesion resistance gene for Asian soybean rust. Theor Appl Genet 2010, 12:1033-1046
40. Lyon E, Wittwer CT: LightCycler technology in molecular diagnostics. J Mol Diagn 2009, 11:93-101
41. Abner CW, McKinnon PJ: The DNA double-strand break response in the nervous system. DNA Repair 2004, 3:1141-1147 (Pubitemid 38997958)
42. Su Y-H, Song J, Wang Z, Wang X, Wang M, Brenner DE, Block TM: Removal of high molecular weight DNA by carboxylated magnetic beads enhances the detection of mutated K-ras DNA in urine. Ann NY Acad Sci 2008, 1137:82-91
43. Kirk GD, Bah E, Montesano R: Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis 2006, 27:2070-2082 (Pubitemid 44530582)
44. Stern MC, Umbach DM, Yu MC, London SJ, Zhang ZQ, Taylor JA: Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001, 10:617-625 (Pubitemid 32703195)
45. Denissenko MF, Koudriakova TB, Smith L, O'Connor TR, Riggs AD, Pfeifer GP: The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene 1998, 17:3007-3014 (Pubitemid 29012203)
46. Soma M: Mice lacking serum amyloid p component do not necessarily develop severe autoimmune disease. Biochem Biophys Res Commun 2001, 286:200-205
47. Jackson PE, Qian GS, Friesen MD, Zhu YR, Lu P, Wang JB, Wu Y, Kensler TW, Vogelstein B, Groopman JD: Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res 2001, 61:33-35 (Pubitemid 32095694)
48. Choo KB, Liu MS, Chang PC, Wu SM, Su MW, Pan CC, Han SH: Analysis of six distinct integrated hepatitis B virus sequences cloned from the cellular DNA of a human hepatocellular carcinoma. Virology 1986, 154:405-408
49. Ng IOL, Guan XY, Poon RT, Fan ST, Lee JM: Determination of the molecular relationship between multiple tumor nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 2003, 199:345-353 (Pubitemid 36266857)
50. Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O: Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology 1999, 29:1446-1452 (Pubitemid 29211046)
51. Whittaker S, Marais R, Zhu AX: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005